Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Cancer Research|December 28, 2013
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignanciesDamian J Green, Nural N Orgun, Jon C Jones, et al.
Blood Advances|October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysisMehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.
Blood Advances|December 15, 2022
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomasRyan C Lynch, Christina Poh, Chaitra S Ujjani, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Blood|April 19, 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHLJordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 19